Express News | Ping An Securities Pharmaceutical Industry 2025 Annual Strategy Report: Exploring new growth from payment sources, focusing on innovation, going overseas, equipment upgrades, and Consumer recovery.

BreakingsDec 15 12:17

kexing biopharm (688136): Profitability continues to improve, achieving breakthroughs in sales in the European Union market.

Kexing Biopharm released its 2024 third-quarter performance report, with the company achieving revenues of 1.038 billion yuan, a year-on-year increase of 7.15%; net income attributable to the parent company was 0.017 billion yuan, a year-on-year increase of 131.63%; non-net profit attributable to the parent company was 0.2 billion yuan.

huaanNov 4 00:00

Kexing Biopharm (688136) Third Quarter Report Review: High growth in exports, continuing to accelerate the overseas commercialization process.

Investment Highlights: Event: The company released the third quarter report of 2024. In the first three quarters of 2024, the revenue was 1.038 billion yuan (+7.15% year-on-year), and the net income attributable to the mother was 17.18 million (+131.6% year-on-year).

swhy research.Oct 30 07:41

Kexing Biopharm (688136): Rapid growth in overseas business, continuous improvement in profitability.

Event: The company released the third quarter report of 2024, achieving revenue of 1.038 billion yuan in the first three quarters (+7.15%), with a net income attributable to shareholders of the listed company of 17.18 million yuan, and a non-net profit attributable to shareholders of 242 million yuan.

Shouchuang SecuritiesOct 30 00:00

Third Quarter Report 2024

SZSIOct 26 00:00 · Announcements

Express News | kexing biopharm: Revenue in the first three quarters was 1.038 billion yuan, a year-on-year increase of 7.15%.

BreakingsOct 25 17:33